0000950170-23-011424.txt : 20230331 0000950170-23-011424.hdr.sgml : 20230331 20230331163944 ACCESSION NUMBER: 0000950170-23-011424 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230330 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acasti Pharma Inc. CENTRAL INDEX KEY: 0001444192 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35776 FILM NUMBER: 23788527 BUSINESS ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 BUSINESS PHONE: 450-686-4555 MAIL ADDRESS: STREET 1: 3009, BOUL. DE LA CONCORDE EAST STREET 2: SUITE 102 CITY: LAVAL STATE: A8 ZIP: H7E 2B5 8-K 1 acst-20230330.htm 8-K 8-K
0001444192false00014441922023-03-302023-03-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2023

 

 

ACASTI PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Quebec

001-35776

98-1359336

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3009, boul. de la Concorde East

Suite 102

 

Laval, Quebec

 

H7E 2B5

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 450 686-4555

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, no par value per share

 

ACST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 30, 2023, Mr. Jean-Marie (John) Canan resigned from the board of directors of Acasti Pharma Inc. (the "Company"), effective immediately. Mr. Canan was also a member of the Company's audit committee and governance and human resources committee. Mr. Canan's resignation was not the result of any dispute or disagreement with the Company or the Company’s board of directors on any matter relating to the operations, policies or practices of the Company.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Acasti Pharma Inc.

 

 

 

 

Date:

March 31, 2023

By:

/s/ Jan D'Alvise

 

 

 

Jan D'Alvise, Chief Executive Officer

 

 EX-101.LAB 2 acst-20230330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 3 acst-20230330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 acst-20230330.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Mar. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 30, 2023
Entity Registrant Name ACASTI PHARMA INC.
Entity Central Index Key 0001444192
Entity Emerging Growth Company false
Securities Act File Number 001-35776
Entity Incorporation, State or Country Code A8
Entity Tax Identification Number 98-1359336
Entity Address, Address Line One 3009, boul. de la Concorde East
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Postal Zip Code H7E 2B5
City Area Code 450
Local Phone Number 686-4555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol ACST
Security Exchange Name NASDAQ
XML 6 acst-20230330_htm.xml IDEA: XBRL DOCUMENT 0001444192 2023-03-30 2023-03-30 0001444192 false 8-K 2023-03-30 ACASTI PHARMA INC. A8 001-35776 98-1359336 3009, boul. de la Concorde East Suite 102 Laval QC H7E 2B5 450 686-4555 false false false false Common Shares, no par value per share ACST NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports acst-20230330.htm acst-20230330.xsd acst-20230330_lab.xml acst-20230330_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acst-20230330.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "acst-20230330.htm" ] }, "labelLink": { "local": [ "acst-20230330_lab.xml" ] }, "presentationLink": { "local": [ "acst-20230330_pre.xml" ] }, "schema": { "local": [ "acst-20230330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20230330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230330.htm", "contextRef": "C_8666a50c-b287-4f9d-af76-1b008cb78fd9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20230330.htm", "contextRef": "C_8666a50c-b287-4f9d-af76-1b008cb78fd9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.acastipharma.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-011424-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-011424-xbrl.zip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